HOME >> MEDICINE >> NEWS
New study reveals promising osteoporosis treatment

A New York University College of Dentistry professor has developed a calcium phosphate-based supplement that -- even at low concentrations -- significantly improves bone strength and thickness without the side effects of many current drug treatments. Dr. Racquel Z. LeGeros, a Professor of Biomaterials and Biomimetics and of Implant Dentistry, presented her research on the supplement at the American Association for Dental Research annual meeting on March 9, 2006.

Current FDA-approved pharmaceutical-based osteoporosis treatments, such as bisphosphonate drugs and hormone therapies, do not effectively repair bone that has already been lost. In fact, bisphosphonates have been shown to actually inhibit bone redevelopment. Many of these treatments also have serious side effects, including increasing the risk of heart disease, strokes, and breast cancer.

But the supplement Dr. LeGeros developed by combining magnesium (Mg), zinc (Zn), and fluoride (F) ions in a calcium-phosphate (CaP) matrix does not have the side effects of the current pharmaceutical-based treatments. Perhaps more importantly, a Mg/Zn/F-CaP supplement would be inexpensive to produce and would not require FDA approval. Dr. LeGeros' formulation could be available to market as an over-the-counter supplement, pending patent approval.

In her study, Dr. LeGeros investigated the effect in rats of Mg/Zn/F-CaP ion combinations on several bone properties: strength, thickness, quality, and composition of bones.

Dr. LeGeros divided a sample of 72 (36 males, 36 females) adult Sprague-Dawley rats (average weight, 160g) into six groups receiving the following diets: control; mineral deficiency-induced osteoporosis (MD); MD supplemented with Mg-CaP; Zn-CaP; F-CaP; and Mg/Zn/F-CaP. Each supplement was 0.6% of the MD diet. The post-mortem examination of the femurs in the MD Mg/Zn/F-CaP group showed that even this small amount of Mg/Zn/F-CaP supplement substantially improved bone streng
'"/>

Contact: Christopher James
christopher.james@nyu.edu
212-998-6876
New York University
9-Mar-2006


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New study reveals promising osteoporosis treatment

(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...
(Date:6/19/2013)... St. Louis, MO (PRWEB) June 19, 2013 ... solutions organization, partnered with ARAMARK Healthcare Technologies to ... equipment management plan with savings of more than ... repair and maintenance service expenditures. , “Driving economies ... the top medical equipment management challenges facing multi-site ...
(Date:6/19/2013)... a world-leading provider of scientific, technical and medical ... of the National Osteoporosis Guideline Group (NOGG) Update ... postmenopausal women and older men in the journal ... Maturitas , the original guidelines have been ... an additional focus on the management of glucocorticoid-induced ...
(Date:6/19/2013)... Mass. (PRWEB) June 19, 2013 ... security solutions, today announced that Imprivata OneSign ® ... KLAS® 2013 Mid-Term Performance Review: Software & Services report ... KLAS laud Imprivata on the superior performance of its ... support, and they indicate that Imprivata is integral to ...
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices Market ... Forecast, 2011 – 2017,” the global endoscopy devices market ... and is expected to reach USD 10.8 billion by ... to 2017. Flexible endoscopes formed the largest category in ... for the year 2011. , Related Report : Medical ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... 19, 2013   Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
Cached News: